Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs VigorMeds

Fitstry
Graded #300

Higher grade

vs+9.5
VigorMeds
Graded #484

Lower grade

The verdict

Fitstry takes it — 61.2/100 to 51.7/100.

Fitstry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fitstry is the GLP-1 weight-loss program of Weightstry, LLC, a LegitScript-certified, cash-pay telehealth practice focused on women 40+.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVigorMeds +16
29
45
Dose & formulationFitstry +35
75
40
Clinical oversightFitstry +11
81
70
Labs & monitoringFitstry +20
73
53
FulfillmentFitstry +7
67
60
Contract termsFitstry +6
47
41
Fitstry · left barVigorMeds · right bar

The numbers

MetricFitstryVigorMeds
WeighScore61.2/10051.7/100
GradeCC
Scorecard rank#300#484
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)Not disclosed
Tirzepatide$269/mo (annual plan, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Fitstry

Graded #300 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
VigorMeds

Graded #484 · C

Strengths

  • Provider-guided GLP-1 weight management via a telehealth consultation, not a pure async questionnaire
  • Care delivered by named, experienced clinicians (Dr. Anthony Kane, Dr. Kevin Kargman, Stephanie Kowatch FNP-C)
  • No-questions-asked 30-day satisfaction guarantee
  • Multi-vertical platform — also offers anti-aging/wellness, ED, and hair-loss treatment
  • Personalized treatment plan with ongoing follow-up and support

Where it loses points

  • Pricing not shown until you create an account and complete the intake
  • Specific GLP-1 medications and forms are not named on the public site
  • States served are not listed on an accessible page
  • Vigormeds LLC is a patient-management platform; prescribing is via OLA Health LLC and independent providers
  • No LegitScript certification or pharmacy-partner details published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard